2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 3217

Macrophage Depletion Using a Specific CSF-1R Kinase Inhibitor Ameliorates Kidney and Skin Disease in a Mouse Model of Systemic Lupus Erythematosus
Abstract Number: 3218

A Randomized, Double-Blind, Placebo-Controlled, 52-Week Study of the Efficacy and Safety of Belimumab Administered Subcutaneously Plus Standard Care to Patients with Systemic Lupus Erythematosus (SLE)
Abstract Number: 3219

Efficacy and Safety of 4 Weeks Administration of Arsenic Trioxide in Moderate Active Systemic Lupus Erythematosus. a Phase I/II Proof-of-Concept Sequential Dose Escalation Multicenter Study
Abstract Number: 3220

Anifrolumab Differentially Suppresses Peripheral Biomarkers of Systemic Lupus Erythematosus Compared with Placebo in a Phase IIb Trial
Abstract Number: 3221

Safety and Efficiency of Low-Dose Interleukin-2 Treatment in Systemic Lupus Erythematosus
Abstract Number: 3222

Repeated Administration of Dapirolizumab Pegol (DZP) Appears Safe and Well Tolerated in Patients with Systemic Lupus Erythematosus (SLE) and Is Accompanied By an Improvement in Disease Activity: Results from a Phase 1 Study
Abstract Number: 3223

Anifrolumab, an Anti-Interferon Alpha Receptor Monoclonal Antibody, in Moderate to Severe Systemic Lupus Erythematosus (SLE)
Abstract Number: 3224

Salivary IL-1 Alpha and IL-1 Beta Levels Are Associated with Oral Mucosal Activity in Behcet’s Disease
Abstract Number: 3225

Whole Exome Sequencing Identifies Rare Protein-Coding Variants in Behcet’s Disease
Abstract Number: 3226

Increased Serum Levels of IgG Antibodies Against to Alpha-Enolase Are Associated with Severity of Oral Ulcers in Patients with Behcet’s Disease
Abstract Number: 3227

Identification of Novel Protein-Coding Genetic Variants Associated with Takayasu Arteritis
Abstract Number: 3228

Sofosbuvir Plus Ribavirin for Hepatitis C Virus Associated Cryoglobulinemia Vasculitis: Vascuvaldic Study
Abstract Number: 3229

Using Exome Sequencing to Identify Novel Genetic Associations with Granulomatosis with Polyangiitis Susceptibility
Abstract Number: 3230

Perceived Barriers in Care for Arthritis
Abstract Number: 3231

A Systematic Review of the Persuasive Design Principles Used in Health Apps for Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].